Pediatric Cancers
Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer
Dexrazoxane appeared to have a cardioprotective effect almost 2 decades after exposure to anthracyclines among a cohort of young adults who survived childhood cancer, according to study results published in Journal of Clinical Oncology.
Disparities observed in geographic access to pediatric cancer care
Approximately 83% of children, adolescents and young adults within the continental United States have access to pediatric cancer care within a 60-minute travel distance, according to a study published in JAMA Network Open.
Wearable device may improve at-home temperature monitoring of children with cancer
For children with hematologic malignancies, a fever may indicate a deadly bloodstream infection and should be addressed as soon as possible.
CCSS
Long-term CV effects of cancer and its associated therapies.
FDA grants orphan drug designation to several oncology therapies
Age cutoff of 14 years may be more suitable than 18 years for pediatric thyroid cancer
A cutoff of age 15 years for pediatric differentiated thyroid cancer care may be more appropriate than the American Thyroid Association’s cutoff of 18 years due to risk factors related to survival rates, according to study data.
FDA approves Rituxan plus chemotherapy for pediatric lymphoma, leukemia
Early intervention key to mitigate neurocognitive effects of pediatric cancer treatment
As cancer treatment options continue to improve, the growing number of childhood cancer survivors will require individualized strategies and risk assessment to help prevent and monitor neurocognitive late effects.
Top in hem/onc: Detecting cancer by smell, COVID-19 vaccine elicits response
Results from a small study showed that an odor-based tool identified ovarian cancer with 95% accuracy and pancreatic cancer with 90% accuracy. A report on the data was the top story in hematology/oncology last week.
Should suspicious pediatric thyroid nodules smaller than 1 cm on ultrasound undergo biopsy?
The American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS), published in 2017, provides a standard system for risk stratification and management of thyroid nodules detected by ultrasound. Nodules are characterized and graded on the basis of sonographic features — including composition, echogenicity, shape, margin and echogenic foci — and assigned a risk level ranging from TR1 (benign) to TR5 (highly suspicious). For TI-RADS categories 3 to 5, the recommendation to proceed to FNA is based upon nodule diameter.